Date: 2025-11-28Category: Press ReleaseState: Union GovernmentCountry: India
Indian Pharmacopoeia Commission signs 3 MoUs with Nagaland Medical Council, Nagaland State Drugs Control Administration (NSDCA) and Nagaland State Pharmacy Council
**Executive Summary**
The Indian Pharmacopoeia Commission (IPC) signed three Memoranda of Understanding (MoUs) on November 28, 2025, with the Nagaland Medical Council, Nagaland State Drugs Control Administration (NSDCA), and Nagaland State Pharmacy Council. These collaborations aim to strengthen pharmacovigilance and materiovigilance, promote adverse event reporting, expand ADR monitoring, and advance safe medicine use through the National Formulary of India in Nagaland. The MoU with the Nagaland Medical Council is the first MoU with any State Medical Council in India.
**Key Points / Main Content**
* **Purpose and Objectives:**
* Strengthen pharmacovigilance and materiovigilance activities in Nagaland.
* Promote adverse event reporting related to drugs and medical devices.
* Build capacity among stakeholders involved in healthcare.
* Expand ADR monitoring centers and Medical Device Monitoring Centers.
* Advance the safe and rational use of medicines, using the National Formulary of India (NFI) as a standard reference across healthcare facilities.
* Advance patient safety initiatives across the state of Nagaland.
* **Collaboration and Commitments:**
* IPC commits to working with the NSDCA, Nagaland State Pharmacy Council and Nagaland Medical Council.
* IPC will provide technical guidance and expert support.
* NSDCA and Nagaland State Pharmacy Council will coordinate with medical colleges, hospitals, pharmacists, drug inspectors, industry stakeholders, and other healthcare professionals.
* **Implementation and Scope:**
* Enhance professional engagement and encourage wider participation in ADR reporting.
* Reinforce medicine safety surveillance mechanisms.
* Promote capacity building for healthcare professionals, including physicians, pharmacists, and nurses.
* Facilitate annual observance of the National Pharmacovigilance Week in collaboration with IPC.
* **Unique Aspects:**
* The MoU with Nagaland Medical Council is the first MoU with any State Medical Council in India.
* The MoU with Nagaland Drugs Control Administration is IPC's second MoU followed by UPFDA and the first of its kind in the North Eastern region.
* The MoU with Nagaland State Pharmacy Council is the fourth State Pharmacy Council in the country to sign an MoU.
**Impact Analysis**
**Nagaland Medical Council, NSDCA, and Nagaland State Pharmacy Council**
* **Impact:** Strengthen collaborative efforts to promote public health by facilitating the use of Indian Pharmacopoeia Reference Substances and Impurity Standards in drug testing laboratories under NSDCA, safe and rational use of medicines, enhancing Pharmacovigilance and Materiovigilance activities, and advancing patient safety initiatives across the state of Nagaland.
* **Action Required:** Coordinate with medical colleges, hospitals, pharmacists, drug inspectors, industry stakeholders, and other healthcare professionals in both public and private healthcare establishments to ensure effective implementation of the agreed activities.
**Healthcare Professionals (Physicians, Pharmacists, Nurses, etc.)**
* **Impact:** Enhanced opportunities for capacity building in pharmacovigilance and materiovigilance practices.
* **Action Required:** Participate in training programs and contribute to ADR reporting and medicine safety surveillance.
**Patients in Nagaland**
* **Impact:** Increased patient safety through improved medication safety and structured capacity building.
* **Action Required:** Not explicitly stated, but implicitly benefit from safer medicine use.
Key Entities Referenced
Indian Pharmacopoeia Commission (IPC): An autonomous institution under the Ministry of Health and Family Welfare responsible for setting standards for drugs in India. It is the primary party signing the MoUs.
Memorandum of Understanding (MoU): Agreements signed to strengthen pharmacovigilance and materiovigilance, promote adverse event reporting, expand ADR monitoring centers and advance safe medicine use.
Nagaland: The state in India where the MoUs are being implemented to improve healthcare facilities and patient safety.
National Formulary of India (NFI): A standard reference document for drug use across healthcare facilities, to be utilized in Nagaland.
Nagaland State Drugs Control Administration (NSDCA): One of the Nagaland entities that signed the MoUs along with the Nagaland Medical Council and Nagaland State Pharmacy Council.
Ministry of Health and Family Welfare
Indian Pharmacopoeia Commission signs 3
MoUs with Nagaland Medical Council, Nagaland
State Drugs Control Administration (NSDCA) and
Nagaland State Pharmacy Council
The collaboration seeks to strengthen pharmacovigilance and
materiovigilance, promote adverse event reporting, build
stakeholder capacity, expand ADR monitoring
centres/MDMCs, and advance safe medicine use through
National Formulary of India across healthcare facilities in
Nagaland
MoU signed with Nagaland Medical Council is the first MoU
with any State Medical Council in India to promote
pharmacovigilance & materiovigilance programmes and
strengthen patient safety up to primary health centres
प्रव तथ: 28 NOV 2025 2:03PM by PIB Delhi
The Indian Pharmacopoeia Commission (IPC), Ghaziabad, an autonomous institution under the Ministry
of Health and Family Welfare, Government of India, signed three Memorandum of Understanding (MoU)
with Nagaland Medical Council, Nagaland State Drugs Control Administration (NSDCA), Department of
Health & Family Welfare, Nagaland and State Pharmacy Council, Government of Nagaland, today, during
the One-Day Training Programme on Pharmacovigilance and Materiovigilance organized by Indian
Pharmacopoeia Commission Ghaziabad in collaboration with Nagaland State Drugs Control
Administration (NSDCA), Department of Health & Family Welfare, Nagaland. The programme was
aimed at strengthening IPC’s collaborative efforts in promoting public health by facilitating the use of
Indian Pharmacopoeia Reference Substances and Impurity Standards in drug testing laboratories under
NSDCA, safe and rational use of medicines, enhancing Pharmacovigilance and Materiovigilance
activities, and advancing patient safety initiatives across the state of Nagaland.The MoU was signed by Dr. V. Kalaiselvan, Secretary-cum-Scientific Director, IPC, with Dr. Kevilhulie
Meyase, Registrar, Nagaland Medical Council and Smt. Imlilila, Assistant Drugs Controller, NSDCA, and
Shri Khele Thorie, Registrar, Nagaland State Pharmacy Council, in the presence of representatives from
these organisations. The inaugural session of the one-day training programme was also attended by Shri
Hoveyda Abbas, AS&FA, MoHFW, Government of India, and Shri Anoop Khinchi, Secretary, Ministry of
Health and Family Welfare, Government of Nagaland.
Notably, the MoU with Nagaland Drugs Control Administration is IPC’s second MoU followed by
UPFDA and the first of its kind in the North Eastern region. The MoU with Nagaland Medical Council is
the first MoU with any State Medical Council in the country for promotion of Pharmacovigilance
Programme of India & Materiovigilance Programme of India aimed to promote patient safety up to the
level of Primary Health Centres in the country. The MoU with the State Pharmacy Council, Governmentof Nagaland, is the fourth state Pharmacy council in the country to sign an MoU for safe and rational use
of medicines, enhancing Pharmacovigilance and Materiovigilance activities, and advancing patient safety
initiatives.
Through this MoU, IPC is committed to work together with all three organisations, NSDCA and Nagaland
State Pharmacy Council and Nagaland Medical Council to strengthen pharmacovigilance and
materiovigilance activities, promoting adverse events reporting with use of drugs/medical devices,
utilization of the National Formulary of India (NFI) as a standard reference document across healthcare
facilities in Nagaland supporting rational dispensing and safe medication practices.
In addition, this MoU will promote capacity building to all stakeholders, including healthcare
professionals (Physicians, Pharmacists, Nurses, etc) involved in pharmacovigilance and materiovigilance
practices, scientific personnel involved in quality control of medical products, and safe use of medicines
through mandatory use of the National Formulary of India & facilitate annual observance of the National
Pharmacovigilance Week in collaboration with IPC.
This MoU is expected to enhance professional engagement, encourage wider participation in ADR
reporting through the establishment of ADR monitoring centres/Medical Device Monitoring centres, and
reinforce medicine safety surveillance mechanisms in the region. IPC is committed to providing all
possible technical guidance and expert support for these initiatives, while NSDCA and Nagaland State
Pharmacy Council will coordinate with Medical Colleges/Hospitals/Pharmacists/Drugs
Inspectors/Industry Stakeholders, and other healthcare professionals in both public and private healthcare
establishments to ensure effective implementation of the agreed activities.
The collaboration between IPC and NSDCA, Nagaland State Pharmacy Council, and Nagaland Medical
Council reflects IPC’s shared commitment to improving medication safety and strengthening patient
safety through structured capacity-building and the promotion of safe use of medicines in the region.
*****
SRHFW/IPC Signs 3 MoUs with NMC, NSDCA & NSPC/28November2025/1
(रलीज़ आईडी: 2195787) आगंतुक पटल : 588
इस वज्ञ को इन भाषाओ ंम पढ़: Urdu , ही , Punjabi